Brief: Casi Pharmaceuticals Enters Into Sublicense Agreement With Tianshi Pharmaceuticals For Anti-Cd38 Monoclonal Antibody Cid-103 In Autoimmune Field
24/05/2022 12:19
May 24 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT
WITH
TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB)
CID-103 IN AUTOIMMUNE FIELD
* CASI PHARMACEUTICALS INC - TO RECEIVE UPFRONT PAYMENT OF
$10
MILLION IN TWO INSTALMENT
* CASI PHARMACEUTICALS INC - THROUGH ITS WHOLLY-OWNED PRC
SUBSIDIARY, WILL HOLD 15% EQUITY OF TIANSHI
Source text for Eikon: ID:nPn7vXz2ba
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary